Specific and sensitive hydrolysis probe-based real-time pcr detection of epidermal growth factor receptor variant III in oral squamous cell carcinoma

PLoS ONE

Volumn 7, Issue 2, 2012, Pages

  McIntyre, John B ^a   Bose, Pinaki ^a   Klimowicz, Alexander C ^a   Brockton, Nigel T ^b   Petrillo, Stephanie ^a   Matthews, Wayne ^a   Easaw, Jay ^a   Magliocco, Anthony ^a   Dort, Joseph C ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b ALBERTA HEALTH SERVICES   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 3; MESSENGER RNA; PROTEIN VARIANT; EPIDERMAL GROWTH FACTOR RECEPTOR; MUTANT PROTEIN; TUMOR PROTEIN;

ADULT; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; EPIDERMAL GROWTH FACTOR RECEPTOR VARIANT III GENE; FEMALE; FLUORESCENCE ANALYSIS; GENE MUTATION; GENE OVEREXPRESSION; GENETIC IDENTIFICATION; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; HYDROLYSIS; IMMUNOHISTOCHEMISTRY; MALE; MOUTH CARCINOMA; MUTATIONAL ANALYSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; SQUAMOUS CELL CARCINOMA; VALIDATION PROCESS; CHEMISTRY; GENETICS; METHODOLOGY; MOUTH TUMOR; STANDARD;

CARCINOMA, SQUAMOUS CELL; HUMANS; HYDROLYSIS; MOUTH NEOPLASMS; MUTANT PROTEINS; NEOPLASM PROTEINS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA, MESSENGER; SENSITIVITY AND SPECIFICITY;

EID: 84857136204     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0031723     Document Type: Article

References (39)

1. Harris TJ, McCormick F, (2010) The molecular pathology of cancer. Nature reviews Clinical oncology 7: 251-265.
2. Mitsudomi T, Yatabe Y, (2010) Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer. The FEBS journal 277: 301-308.
3. Lai SY, Johnson FM, (2010) Defining the role of the JAK-STAT pathway in head and neck and thoracic malignancies: implications for future therapeutic approaches. Drug resistance updates: reviews and commentaries in antimicrobial and anticancer chemotherapy 13: 67-78.
4. Zhang Z, Stiegler AL, Boggon TJ, Kobayashi S, Halmos B, (2010) EGFR-mutated lung cancer: a paradigm of molecular oncology. Oncotarget 1: 497-514.
5. Moscatello DK, Holgado-Madruga M, Godwin AK, Ramirez G, Gunn G, et al. (1995) Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer research 55: 5536-5539.
6. Wikstrand CJ, Hale LP, Batra SK, Hill ML, Humphrey PA, et al. (1995) Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer research 55: 3140-3148.
7. Batra SK, Castelino-Prabhu S, Wikstrand CJ, Zhu X, Humphrey PA, et al. (1995) Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRvIII gene. Cell growth & differentiation: the molecular biology journal of the American Association for Cancer Research 6: 1251-1259.
8. Biernat W, Huang H, Yokoo H, Kleihues P, Ohgaki H, (2004) Predominant expression of mutant EGFR (EGFRvIII) is rare in primary glioblastomas. Brain pathology 14: 131-136.
9. Sasaki H, Kawano O, Endo K, Yukiue H, Yano M, et al. (2007) EGFRvIII mutation in lung cancer correlates with increased EGFR copy number. Oncology reports 17: 319-323.
10. Lammering G, Hewit TH, Holmes M, Valerie K, Hawkins W, et al. (2004) Inhibition of the type III epidermal growth factor receptor variant mutant receptor by dominant-negative EGFR-CD533 enhances malignant glioma cell radiosensitivity. Clinical cancer research: an official journal of the American Association for Cancer Research 10: 6732-6743.
11. Montgomery RB, Guzman J, O'Rourke DM, Stahl WL, (2000) Expression of oncogenic epidermal growth factor receptor family kinases induces paclitaxel resistance and alters beta-tubulin isotype expression. The Journal of biological chemistry 275: 17358-17363.
12. Yamazaki H, Ohba Y, Tamaoki N, Shibuya M, (1990) A deletion mutation within the ligand binding domain is responsible for activation of epidermal growth factor receptor gene in human brain tumors. Japanese journal of cancer research: Gann 81: 773-779.
13. Ekstrand AJ, Sugawa N, James CD, Collins VP, (1992) Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails. Proceedings of the National Academy of Sciences of the United States of America 89: 4309-4313.
14. Wong AJ, Ruppert JM, Bigner SH, Grzeschik CH, Humphrey PA, et al. (1992) Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proceedings of the National Academy of Sciences of the United States of America 89: 2965-2969.
15. Heimberger AB, Hlatky R, Suki D, Yang D, Weinberg J, et al. (2005) Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients. Clinical cancer research: an official journal of the American Association for Cancer Research 11: 1462-1466.
16. Garcia de Palazzo IE, Adams GP, Sundareshan P, Wong AJ, Testa JR, et al. (1993) Expression of mutated epidermal growth factor receptor by non-small cell lung carcinomas. Cancer research 53: 3217-3220.
17. Ji H, Zhao X, Yuza Y, Shimamura T, Li D, et al. (2006) Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors. Proceedings of the National Academy of Sciences of the United States of America 103: 7817-7822.
18. Olapade-Olaopa EO, Moscatello DK, MacKay EH, Horsburgh T, Sandhu DP, et al. (2000) Evidence for the differential expression of a variant EGF receptor protein in human prostate cancer. British journal of cancer 82: 186-194.
19. Ozanne B, Richards CS, Hendler F, Burns D, Gusterson B, (1986) Over-expression of the EGF receptor is a hallmark of squamous cell carcinomas. The Journal of pathology 149: 9-14.
20. Grandis JR, Tweardy DJ, (1993) TGF-alpha and EGFR in head and neck cancer. Journal of cellular biochemistry Supplement 17F: 188-191.
21. Hama T, Yuza Y, Saito Y, Ou J, Kondo S, et al. (2009) Prognostic significance of epidermal growth factor receptor phosphorylation and mutation in head and neck squamous cell carcinoma. The oncologist 14: 900-908.
22. Sok JC, Coppelli FM, Thomas SM, Lango MN, Xi S, et al. (2006) Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clinical cancer research: an official journal of the American Association for Cancer Research 12: 5064-5073.
23. Chau NG, Perez-Ordonez B, Zhang K, Pham NA, Ho J, et al. (2011) The association between EGFR variant III, HPV, p16, c-MET, EGFR gene copy number and response to EGFR inhibitors in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Head & neck oncology 3: 11.
24. Leemans CR, Braakhuis BJ, Brakenhoff RH, (2011) The molecular biology of head and neck cancer. Nature reviews Cancer 11: 9-22.
25. Yang B, Chen J, Zhang X, Cao J, (2009) Expression of Epidermal Growth Factor Receptor variant III in laryngeal carcinoma tissues. Auris, nasus, larynx 36: 682-687.
26. Takes RP, Baatenburg de Jong RJ, Schuuring E, Litvinov SV, Hermans J, et al. (1998) Differences in expression of oncogenes and tumor suppressor genes in different sites of head and neck squamous cell. Anticancer research 18: 4793-4800.
27. Bernier J, Bentzen SM, Vermorken JB, (2009) Molecular therapy in head and neck oncology. Nature reviews Clinical oncology 6: 266-277.
28. Yoshimoto K, Dang J, Zhu S, Nathanson D, Huang T, et al. (2008) Development of a real-time RT-PCR assay for detecting EGFRvIII in glioblastoma samples. Clinical cancer research: an official journal of the American Association for Cancer Research 14: 488-493.
29. Frederick L, Eley G, Wang XY, James CD, (2000) Analysis of genomic rearrangements associated with EGRFvIII expression suggests involvement of Alu repeat elements. Neuro-oncology 2: 159-163.
30. Mellinghoff IK, Wang MY, Vivanco I, Haas-Kogan DA, Zhu S, et al. (2005) Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. The New England journal of medicine 353: 2012-2024.
31. Camp RL, Chung GG, Rimm DL, (2002) Automated subcellular localization and quantification of protein expression in tissue microarrays. Nature medicine 8: 1323-1327.
32. Wikstrand CJ, McLendon RE, Friedman AH, Bigner DD, (1997) Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII. Cancer research 57: 4130-4140.
33. Vokes EE, Weichselbaum RR, Lippman SM, Hong WK, (1993) Head and neck cancer. The New England journal of medicine 328: 184-194.
34. Farah CS, McCullough MJ, (2008) Oral cancer awareness for the general practitioner: new approaches to patient care. Australian dental journal 53: 2-10 quiz 99.
35. Soulieres D, Senzer NN, Vokes EE, Hidalgo M, Agarwala SS, et al. (2004) Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 22: 77-85.
36. Siu LL, Soulieres D, Chen EX, Pond GR, Chin SF, et al. (2007) Phase I/II trial of erlotinib and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Princess Margaret Hospital phase II consortium and National Cancer Institute of Canada Clinical Trials Group Study. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 25: 2178-2183.
37. Stewart JS, Cohen EE, Licitra L, Van Herpen CM, Khorprasert C, et al. (2009) Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected]. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 27: 1864-1871.
38. Monteiro LS, Diniz-Freitas M, Garcia-Caballero T, Forteza J, Fraga M, (2010) EGFR and Ki-67 expression in oral squamous cell carcinoma using tissue microarray technology. Journal of oral pathology & medicine: official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology 39: 571-578.
39. Pao W, Kris MG, Iafrate AJ, Ladanyi M, Janne PA, et al. (2009) Integration of molecular profiling into the lung cancer clinic. Clinical cancer research: an official journal of the American Association for Cancer Research 15: 5317-5322.